Citations

Clear

2303 citation(s) found for "Yu, Edward".

Changes in National Google Trends and Local Healthcare Utilization After High-Impact Gastroenterology Publications
Kamboj, Amrit K. , Chedid, Victor , Iyer, Prasad G. , Bailey, Kent R. , Harmsen, William S. , Katzka, David A. , Agarwal, Siddharth , Chedid, Victor G , Agarwal, Siddharth , Agarwal, Siddharth

Mayo Clinic

American Journal of Gastroenterology | September 17, 2021 | Volume: 116 | Issue: 12 | Pages: 2465-2469

10.14309/ajg.0000000000001516 | PMID 34534126 Get It

INTRODUCTION: We examined national Google Trends and local healthcare utilization after 3 high-impact gastroenterology publications. METHODS: Changes in US Google Trends and Olmsted County health utilization were studied. RESULTS: Publication views within 30 days were 51,458 ( Imperiale ), 49,759 ( Pimentel ), and 18,750 ( Gomm ). Colonoscopy searches ( P = 0.04) and Cologuard tests performed ( P < 0.01) increased while colonoscopies decreased ( P < 0.01). Searches for rifaximin ( P = 0.05), irritable bowel syndrome ( P < 0.01), diarrhea ( P < 0.01), and rifaximin prescriptions ( P = 0.02) increased. Increase in hydrogen-2 blocker searches ( P = 0.02) and prescriptions ( P < 0.01) and gastroesophageal reflux disease ( P < 0.01) and dementia office visits ( P < 0.01) occurred. DISCUSSION: High-impact gastroenterology publications influence Google searches and local population-based healthcare utilization.
Vulvar Crohn's Disease: Clinical Features and Outcomes
Cho, Janice , Loftus, Edward V. , Bruining, David H. , Chedid, Victor , Faubion, William A. , Johnson, Amanda M. , Kane, Sunanda V. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Picco, Michael F., Raffals, Laura E. , Schroeder, Kenneth W., Tremaine, William J., Cho, Janice M, Chedid, Victor G , Loftus, Edward V , Farraye, Francis A. , Kisiel, John B. , Malik, Talha A. , Coelho–Prabhu, Nayantara

Mayo Clinic

American Journal of Gastroenterology | September 9, 2021 | Volume: 116 | Issue: 11 | Pages: 2296-2299

10.14309/ajg.0000000000001502 | PMID 34732676 Get It

INTRODUCTION: Vulvar involvement is a rare complication of Crohn's disease (CD). The optimal treatment of vulvar CD is unknown. METHODS: We conducted a 25-year retrospective cohort study of vulvar CD from 3 referral centers. Clinical features and outcomes were studied. RESULTS: Fifty patients were identified. The most common vulvar symptoms were pain (74%), edema (60%), ulcerations (46%), nodules (36%), and abscess (34%). Medical management leading to symptomatic improvement varied, and 5 patients ultimately required surgery. DISCUSSION: Vulvar CD manifests with a broad spectrum of symptoms. Aggressive medical management was frequently effective, although surgery was required in 10% of cases.
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Costa, Luciano J. , Monohan, Gregory, Kovacsovics, Tibor , Burwick, Nicholas , Kaufman, Jonathan L. , Hong, Wan‐Jen , Dail, Monique , Masud, Abdullah Al , Munasinghe, Wijith, Ross, Jeremy A. , Bueno, Orlando F. , Kumar, Shaji , Stadtmauer, Edward A. , Kaufman, Jonathan L , Dail, Monique , Kumar, Shaji K , Costa, Luciano J , Davies, Faith E. , Jakubowiak, Andrzej , Salem, Ahmed Hamed , Yang, Xiaoqing

Mayo Clinic

Blood Advances | September 1, 2021 | Volume: 5 | Issue: 19 | Pages: 3748-3759

10.1182/bloodadvances.2020004146 | PMID 34470049 Get It

Abstract Proteins in the antiapoptotic B-cell lymphoma 2 (BCL-2) family play a role in the pathophysiology of multiple myeloma (MM). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis of MM cells, and its efficacy may be potentiated through combination with agents that increase BCL-2 dependency or have complementary mechanisms of action. The safety, tolerability, pharmacokinetics, and antitumor activity of venetoclax in combination with carfilzomib and dexamethasone (VenKd) in adults with relapsed/refractory MM (RRMM) were investigated in this phase 2 dose-escalation study. Oral venetoclax (400 or 800 mg) was administered daily in combination with intravenous carfilzomib (27, 56, or 70 mg/m2) and oral dexamethasone (20 or 40 mg) in 4 dose-finding cohorts. The expansion cohort received venetoclax 800 mg, carfilzomib 70 mg/m2, and dexamethasone 40 mg. Forty-nine patients received treatment. Median prior lines of therapy was 1 (range, 1-3), and median time in the study was 27 months. The most common treatment-emergent adverse events were diarrhea (65%), fatigue (47%), nausea (47%), and lymphopenia (35%). Serious adverse events occurred in 26 (53%) patients. Of 3 treatment-emergent deaths, 1 was considered treatment related. The overall response rate was 80% in all patients, 92% in patients with t(11;14) (n = 13), and 75% in patients without (n = 36). The rate of complete response or better was 41%. Median progression-free survival was 22.8 months. Treatment with VenKd was well tolerated and showed promising response rates in this RRMM patient population, with greater responses observed in patients with t(11;14). This trial is registered at www.clinicaltrials.gov as #NCT02899052.
Introduction. Translational research advances in the evaluation and management of moyamoya disease
Smith, Edward R. , Steinberg, Gary K. , Xu, Bin , Steinberg, Gary K , Smith, Edward , Lanzino, Giuseppe

Mayo Clinic

Neurosurgical Focus | September 1, 2021 | Volume: 51 | Issue: 3 | Pages: E1

10.3171/2021.6.focus21373 | PMID 34469864 Get It

Peripheral nerve block anesthesia/analgesia for patients undergoing primary hip and knee arthroplasty: recommendations from the International Consensus on Anesthesia-Related Outcomes after Surgery (ICAROS) group based on a systematic review and meta-analys
Memtsoudis, Stavros G. , Cozowicz, Crispiana , Bekeris, Janis, Bekere, Dace, Liu, Jiabin , Soffin, Ellen M. , Mariano, Edward R. , Johnson, Rebecca L. , Go, George , Hargett, Mary J. , Lee, Bradley H. , Wendel, Pamela , Brouillette, Mark , Kim, Sang Jo, Baaklini, Lila , Wetmore, Douglas S., Hong, Genewoo , Goto, Rie , Jivanelli, Bridget , Athanassoglou, Vassilis , Αrgyra, Eriphili, Barrington, Michael J. , Borgeat, Alain , El‐Boghdadly, Kariem , Elkassabany, Nabil , Gautier, Philippe , Gerner, Peter, Valle, Alejandro González Della , Goytizolo, Enrique A. , Guo, Zhenggang , Hogg, Rosemary , Kehlet, Henrik , Kessler, Paul, Lavand"homme, Patricia, Macfarlane, Alan , McIsaac, Dan , Neal, Joseph M. , Peng, Philip , Pichler, Lukas, Poultsides, Lazaros, Sites, Brian D. , Stundner, Ottokar , Sun, Eric, Viscusi, Eugene R. , Votta‐Velis, E. Gina, YaDeau, Jacques T. , Sharrock, Nigel E. , Barrington, Michael John , El-Boghdadly, K , Elkassabany, Nabil M , Kopp, Sandra , Mantilla, Carlos, Neal, Joseph M , Poeran, Jashvant , Schwenk, Eric S , Stundner, Ottokar , Viscusi, Eugene , Wu, Christopher L , Mariano, Edward R , Johnson, Rebecca L , Soffin, Ellen M , Macfarlane, Alan James Robert , Andrés, José De , Kessler, Paul, Kopp, Sandra L. , Lavand"homme, Patricia, MacLean, Catherine H. , Mantilla, Carlos B. , McLawhorn, Alexander S. , Parks, Michael L. , Parvizi, Javad , Schwenk, Eric S.

Mayo Clinic

Regional Anesthesia & Pain Medicine | August 25, 2021 | Volume: 46 | Issue: 11 | Pages: 971-985

10.1136/rapm-2021-102750 | PMID 34433647 Get It

Background Evidence-based international expert consensus regarding the impact of peripheral nerve block (PNB) use in total hip/knee arthroplasty surgery. Methods A systematic review and meta-analysis: randomized controlled and observational studies investigating the impact of PNB utilization on major complications, including mortality, cardiac, pulmonary, gastrointestinal, renal, thromboembolic, neurologic, infectious, and bleeding complications. Medline, PubMed, Embase, and Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, were queried from 1946 to August 4, 2020. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess evidence quality and for the development of recommendations. Results Analysis of 122 studies revealed that PNB use (compared with no use) was associated with lower ORs for (OR with 95% CIs) for numerous complications (total hip and knee arthroplasties (THA/TKA), respectively): cognitive dysfunction (OR 0.30, 95% CI 0.17 to 0.53/OR 0.52, 95% CI 0.34 to 0.80), respiratory failure (OR 0.36, 95% CI 0.17 to 0.74/OR 0.37, 95% CI 0.18 to 0.75), cardiac complications (OR 0.84, 95% CI 0.76 to 0.93/OR 0.83, 95% CI 0.79 to 0.86), surgical site infections (OR 0.55 95% CI 0.47 to 0.64/OR 0.86 95% CI 0.80 to 0.91), thromboembolism (OR 0.74, 95% CI 0.58 to 0.96/OR 0.90, 95% CI 0.84 to 0.96) and blood transfusion (OR 0.84, 95% CI 0.83 to 0.86/OR 0.91, 95% CI 0.90 to 0.92). Conclusions Based on the current body of evidence, the consensus group recommends PNB use in THA/TKA for improved outcomes. Recommendation: PNB use is recommended for patients undergoing THA and TKA except when contraindications preclude their use. Furthermore, the alignment of provider skills and practice location resources needs to be ensured. Evidence level: moderate; recommendation: strong.
Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
Wheless, James W. , Miller, Ian , Dlugos, Dennis , Biton, Victor, Cascino, Gregory D. , Sperling, Michael R. , Liow, Kore , Vázquez, Blanca , Segal, Eric , Mauney, Weldon, Desai, Jay , Group, for the DIAZ.001.05 Study, Hogan, R Edward , Sperling, Michael R , Carrazana, Enrique , Miller, Ian , Wheless, James W , Tarquinio, Daniel Charles , Rabinowicz, Adrián L. , Carrazana, Enrique , Group, for the DIAZ.001.05 Study

Mayo Clinic

Epilepsia | August 21, 2021 | Volume: 62 | Issue: 10 | Pages: 2485-2495

10.1111/epi.17041 | PMID 34418086 Get It

Abstract Objective A Phase 3 open‐label safety study (NCT02721069) evaluated long‐term safety of diazepam nasal spray (Valtoco) in patients with epilepsy and frequent seizure clusters. Methods Patients were 6–65 years old with diagnosed epilepsy and seizure clusters despite stable antiseizure medications. The treatment period was 12 months, with study visits at Day 30 and every 60 days thereafter, after which patients could elect to continue. Doses were based on age and weight. Seizure and treatment information was recorded in diaries. Treatment‐emergent adverse events (TEAEs), nasal irritation, and olfactory changes were recorded. Results Of 163 patients in the safety population, 117 (71.8%) completed the study. Duration of exposure was ≥12 months for 81.6% of patients. There was one death (sudden unexpected death in epilepsy) and one withdrawal owing to a TEAE (major depression), both considered unlikely to be related to treatment. Diazepam nasal spray was administered 4390 times for 3853 seizure clusters, with 485 clusters treated with a second dose within 24 h; 53.4% of patients had monthly average usage of one to two doses, 41.7% two to five doses, and 4.9% more than five doses. No serious TEAEs were considered to be treatment related. TEAEs possibly or probably related to treatment ( n = 30) were most commonly nasal discomfort (6.1%); headache (2.5%); and dysgeusia, epistaxis, and somnolence (1.8% each). Only 13 patients (7.9%) showed nasal irritation, and there were no relevant olfactory changes. The safety profile of diazepam nasal spray was generally similar across subgroups based on age, monthly usage, concomitant benzodiazepine therapy, or seasonal allergy/rhinitis. Significance In this large open‐label safety study, the safety profile of diazepam nasal spray was consistent with the established profile of rectal diazepam, and the high retention rate supports effectiveness in this population. A second dose was used in only 12.6% of seizure clusters.
Benzodiazepine administration patterns before escalation to second‐line medications in pediatric refractory convulsive status epilepticus
Sheehan, Theodore , Amengual‐Gual, Marta , Vasquez, Alejandra , Abend, Nicholas S. , Anderson, Anne E. , Arya, Ravindra , Aguilar, Cristina Barcia , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Gaínza‐Lein, Marina , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Jackson, Michele , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Reece, Latania, Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Shellhaas, Renée A. , Smith, Garnett , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Arya, Ravindra , Barcia Aguilar, Cristina , Farias-Moeller, Raquel , Gaillard, William D , Gaínza-Lein, Marina , Guerriero, Rejean M , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Shellhaas, Renée A , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Sheehan, Theodore , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | August 21, 2021 | Volume: 62 | Issue: 11 | Pages: 2766-2777

10.1111/epi.17043 | PMID 34418087 Get It

Abstract Objective This study was undertaken to evaluate benzodiazepine (BZD) administration patterns before transitioning to non‐BZD antiseizure medication (ASM) in pediatric patients with refractory convulsive status epilepticus (rSE). Methods This retrospective multicenter study in the United States and Canada used prospectively collected observational data from children admitted with rSE between 2011 and 2020. Outcome variables were the number of BZDs given before the first non‐BZD ASM, and the number of BZDs administered after 30 and 45 min from seizure onset and before escalating to non‐BZD ASM. Results We included 293 patients with a median (interquartile range) age of 3.8 (1.3–9.3) years. Thirty‐six percent received more than two BZDs before escalating, and the later the treatment initiation was after seizure onset, the less likely patients were to receive multiple BZD doses before transitioning (incidence rate ratio [IRR] = .998, 95% confidence interval [CI] = .997–.999 per minute, p = .01). Patients received BZDs beyond 30 and 45 min in 57.3% and 44.0% of cases, respectively. Patients with out‐of‐hospital seizure onset were more likely to receive more doses of BZDs beyond 30 min (IRR = 2.43, 95% CI = 1.73–3.46, p < .0001) and beyond 45 min (IRR = 3.75, 95% CI = 2.40–6.03, p < .0001) compared to patients with in‐hospital seizure onset. Intermittent SE was a risk factor for more BZDs administered beyond 45 min compared to continuous SE (IRR = 1.44, 95% CI = 1.01–2.06, p = .04). Forty‐seven percent of patients ( n = 94) with out‐of‐hospital onset did not receive treatment before hospital arrival. Among patients with out‐of‐hospital onset who received at least two BZDs before hospital arrival ( n = 54), 48.1% received additional BZDs at hospital arrival. Significance Failure to escalate from BZDs to non‐BZD ASMs occurs mainly in out‐of‐hospital rSE onset. Delays in the implementation of medical guidelines may be reduced by initiating treatment before hospital arrival and facilitating a transition to non‐BZD ASMs after two BZD doses during handoffs between prehospital and in‐hospital settings.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Bradley, Kristin , Campos, Susana M. , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Diver, Elisabeth , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Han, Ernest , Howitt, Brooke E. , Huh, Warner K. , Mariani, Andrea , Nekhlyudov, Larissa , Podoll, Mirna, Remmenga, Steven W., Reynolds, R. Kevin, Salani, Ritu , Sisodia, Rachel , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , Zanotti, Kristine , McMillian, Nicole R., Motter, Angela D., Chu, Christina , Cohn, David E. , Crispens, Marta Ann , George, Suzanne , Lea, Jayanthi Sivasothy , Mutch, David G. , Tanner, Edward J. , Wethington, Stephanie L.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 20, 2021 | Volume: 19 | Issue: 8 | Pages: 888-895

10.6004/jnccn.2021.0038 | PMID 34416706 Get It

The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer or uterine sarcoma. These NCCN Guidelines Insights focus on the recent addition of molecular profiling information to aid in accurate diagnosis, classification, and treatment of uterine sarcomas.
Photodynamic priming with triple‐receptor targeted nanoconjugates that trigger T cell‐mediated immune responses in a 3D in vitro heterocellular model of pancreatic cancer
Silva, Pushpamali De , Bano, Shazia , Wang, Kenneth K. , Maytin, Edward V. , Hasan, Tayyaba , De Silva, Pushpamali , Hasan, Tayyaba , Pogue, Brian W.

Mayo Clinic

Nanophotonics | August 18, 2021 | Volume: 10 | Issue: 12 | Pages: 3199-3214

10.1515/nanoph-2021-0304 | PMID 37485044 Get It

Abstract Photodynamic priming ( PDP ), a collateral effect of photodynamic therapy, can transiently alter the tumor microenvironment (TME) beyond the cytotoxic zone. Studies have demonstrated that PDP increases tumor permeability and modulates immune‐stimulatory effects by inducing immunogenic cell death, via the release of damage‐associated molecular patterns and tumor‐associated antigens. Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of cancers with a stubborn immunosuppressive TME and a dense stroma, representing a challenge for current molecular targeted therapies often involving macromolecules. We, therefore, tested the hypothesis that PDP’s TME modulation will enable targeted therapy and result in immune stimulation. Using triple‐receptor‐targeted photoimmuno‐nanoconjugate (TR‐PINs)‐mediated PDP , targeting epidermal growth factor receptor, transferrin receptor, and human epidermal growth factor receptor 2 we show light dose‐dependent TR‐PINs mediated cytotoxicity in human PDAC cells (MIA PaCa‐2), co‐cultured with human pancreatic cancer‐associated fibroblasts (PCAFs) in spheroids. Furthermore, TR‐PINs induced the expression of heat shock proteins (Hsp60, Hsp70), Calreticulin, and high mobility group box 1 in a light dose and time‐dependent manner. TR‐PINs‐mediated T cell activation was observed in co‐cultures of immune cells with the MIA PaCa‐2‐PCAF spheroids. Both CD4 + T and CD8 + T cells showed light dose and time‐dependant antitumor reactivity by upregulating degranulation marker CD107a and interferon‐gamma post‐PDP. Substantial tumor cell death in immune cell‐spheroid co‐cultures by day 3 shows the augmentation by antitumor T cell activation and their ability to recognize tumors for a light dose‐dependent kill. These data confirm enhanced destruction of heterogeneous pancreatic spheroids mediated by PDP ‐induced phototoxicity, TME modulation and increased immunogenicity with targeted nanoconstructs.
Spectroscopic label-free microscopy of changes in live cell chromatin and biochemical composition in transplantable organoids
Pettinato, Giuseppe , Coughlan, Mark F. , Zhang, Xuejun , Chen, Liming , Khan, Umar , Glyavina, Maria , Sheil, Conor J. , Upputuri, Paul Kumar , Zakharov, Yuri N. , Vitkin, Edward , D’Assoro, Antonino B. , Fisher, Robert A. , Itzkan, Irving, Zhang, Lei , Qiu, Le , Perelman, Lev T. , Upputuri, Paul K

Mayo Clinic

Science Advances | August 18, 2021 | Volume: 7 | Issue: 34 | Pages: No page available

10.1126/sciadv.abj2800 | PMID 34407934 Get It

Formation of transplantable reproducible hiPSC organoids can be aided with real-time label-free intracellular spectroscopy.